Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Gastric and Esophageal Cancer
NCT03281369Phase 2Terminated
- Sponsor
- Roche
- Start
- Oct 2017
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal carcinoma (12 arms), sponsored by Roche. Primary endpoint: Objective Response Rate up to 84.2 months. Started Oct 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal carcinoma
Beyond the preview
Go deeper on NCT03281369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281369.